{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:10:24Z","timestamp":1783703424386,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Uterine fibroids are common benign tumors that occur in up to 80% of women. Approximately half of the women affected experience considerable physical, psychological, and economic burdens and impact on quality of life due to symptoms such as heavy menstrual bleeding, pelvic pain, and infertility. Several medical and surgical options are available to treat uterine fibroids; however, healthcare providers may benefit from practical guidance in the development of individualized treatment plans based on a personalized approach. Medical treatments and minimally invasive procedures are generally preferred by most patients before considering more invasive, higher risk surgical interventions. In general, patient-centered, uterine-preserving procedures may be prioritized based on the patient\u2019s goals and the clinical scenario. Occasionally, hysterectomy may be the preferred treatment option for some patients who require definitive treatment. This call-to-action highlights recent challenges to patient care, including radical shifts in physician\u2013patient interactions due to the COVID-19 pandemic and recent changes to evidence-based, clinically approved therapies. This report also reviews contemporary recommendations for women\u2019s health providers in the diagnosis and medical and surgical management of uterine fibroids. This call-to-action aims to empower healthcare providers to optimize the quality of care for women with uterine fibroids utilizing the best available evidence and best practices.<\/jats:p>","DOI":"10.1007\/s43032-022-00877-3","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T21:02:26Z","timestamp":1645131746000},"page":"1188-1196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A Call-to-Action for Clinicians to Implement Evidence-Based Best Practices When Caring for Women with Uterine Fibroids"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3437-0723","authenticated-orcid":false,"given":"Nicholas","family":"Leyland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ally","family":"Murji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir S.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Al-Hendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/uog.22047","volume":"55","author":"T Bourne","year":"2020","unstructured":"Bourne T, Leonardi M, Kyriacou C, et al. ISUOG consensus statement on rationalization of gynecological ultrasound services in context of SARS-CoV-2. Ultrasound Obstet Gynecol. 2020;55:879\u201385.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"877_CR2","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1097\/AOG.0000000000004401","volume":"137","author":"American College of Obstetricians and Gynecologists","year":"2021","unstructured":"American College of Obstetricians and Gynecologists. Management of symptomatic uterine leiomyomas: ACOG practice bulletin, number 228. Obstet Gynecol. 2021;137:e100\u201315.","journal-title":"Obstet Gynecol"},{"key":"877_CR3","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","volume":"372","author":"EA Stewart","year":"2015","unstructured":"Stewart EA. Clinical practice. Uterine fibroids N Engl J Med. 2015;372:1646\u201355.","journal-title":"Uterine fibroids N Engl J Med"},{"key":"877_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","volume":"188","author":"DD Baird","year":"2003","unstructured":"Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"877_CR5","doi-asserted-by":"crossref","unstructured":"Go VAA, Thomas MC, Singh B, et al. A systematic review of the psychosocial impact of fibroids before and after treatment. Am J Obstet Gynecol. 2020;223:674\u2013708 e8.","DOI":"10.1016\/j.ajog.2020.05.044"},{"issue":"211","key":"877_CR6","first-page":"e1","volume":"206","author":"ER Cardozo","year":"2012","unstructured":"Cardozo ER, Clark AD, Banks NK, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol. 2012;206(211):e1-9.","journal-title":"Am J Obstet Gynecol"},{"key":"877_CR7","unstructured":"Hartmann KE, Fonnesbeck C, Surawicz T, et al. Management of uterine fibroids. AHRQ comparative effectiveness review. Rockville, MD. 2017. Available at: https:\/\/effectivehealthcare.ahrq.gov\/sites\/default\/files\/pdf\/cer-195-uterine-fibroids-final-revision.pdf. Accessed 05 May 2021."},{"key":"877_CR8","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0029-7844(97)00534-6","volume":"90","author":"LM Marshall","year":"1997","unstructured":"Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90:967\u201373.","journal-title":"Obstet Gynecol"},{"key":"877_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajog.2013.08.008","volume":"210","author":"HM Eltoukhi","year":"2014","unstructured":"Eltoukhi HM, Modi MN, Weston M, et al. The health disparities of uterine fibroid tumors for African American women: a public health issue. Am J Obstet Gynecol. 2014;210:194\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"877_CR10","doi-asserted-by":"crossref","unstructured":"Marsh EE, Al-Hendy A, Kappus D, et al. Burden, prevalence, and treatment of uterine fibroids: a survey of U.S. women. J Womens Health (Larchmt). 2018;27:1359\u201367.","DOI":"10.1089\/jwh.2018.7076"},{"key":"877_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/uog.14806","volume":"46","author":"T Van den Bosch","year":"2015","unstructured":"Van den Bosch T, Dueholm M, Leone FP, et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol. 2015;46:284\u201398.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"877_CR12","doi-asserted-by":"publisher","first-page":"E506","DOI":"10.9778\/cmajo.20200004","volume":"8","author":"O Bougie","year":"2020","unstructured":"Bougie O, Bedaiwy MA, Laberge P, et al. Quality of ultrasonography reporting and factors associated with selection of imaging modality for uterine fibroids in Canada: results from a prospective cohort registry. CMAJ Open. 2020;8:E506\u201313.","journal-title":"CMAJ Open"},{"key":"877_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jum.14676","volume":"38","author":"M Zhang","year":"2019","unstructured":"Zhang M, Wasnik AP, Masch WR, et al. Transvaginal ultrasound shear wave elastography for the evaluation of benign uterine pathologies: a prospective pilot study. J Ultrasound Med. 2019;38:149\u201355.","journal-title":"J Ultrasound Med"},{"key":"877_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bpobgyn.2015.11.014","volume":"34","author":"AC Testa","year":"2016","unstructured":"Testa AC, Di Legge A, Bonatti M, et al. Imaging techniques for evaluation of uterine myomas. Best Pract Res Clin Obstet Gynaecol. 2016;34:37\u201353.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"877_CR15","doi-asserted-by":"crossref","unstructured":"Gorgulu FF, Okcu NT. Which imaging method is better for the differentiation of adenomyosis and uterine fibroids? J Gynecol Obstet Hum Reprod. 2021;50:102002.","DOI":"10.1016\/j.jogoh.2020.102002"},{"key":"877_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijgo.2010.11.011","volume":"113","author":"MG Munro","year":"2011","unstructured":"Munro MG, Critchley HO, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:3\u201313.","journal-title":"Int J Gynaecol Obstet"},{"key":"877_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijgo.12666","volume":"143","author":"MG Munro","year":"2018","unstructured":"Munro MG, Critchley HOD, Fraser IS, et al. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018;143:393\u2013408.","journal-title":"Int J Gynaecol Obstet"},{"key":"877_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/humupd\/dmv030","volume":"21","author":"AE Commandeur","year":"2015","unstructured":"Commandeur AE, Styer AK, Teixeira JM. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. Hum Reprod Update. 2015;21:593\u2013615.","journal-title":"Hum Reprod Update"},{"key":"877_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1186\/s12885-020-07003-z","volume":"20","author":"G Zhang","year":"2020","unstructured":"Zhang G, Yu X, Zhu L, et al. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid. BMC Cancer. 2020;20:514.","journal-title":"BMC Cancer"},{"key":"877_CR20","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00296-021-04863-x","volume":"41","author":"M Chevallard","year":"2021","unstructured":"Chevallard M, Belloli L, Ughi N, et al. Use of telemedicine during the COVID-19 pandemic in patients with inflammatory arthritis: a retrospective study on feasibility and impact on patient-reported outcomes in a real-life setting. Rheumatol Int. 2021;41:1253\u201361.","journal-title":"Rheumatol Int"},{"key":"877_CR21","doi-asserted-by":"crossref","unstructured":"Walia B, Shridhar A, Arasu P, et al. US physicians\u2019 perspective on the sudden shift to telehealth: survey study. JMIR Hum Factors. 2021;8:e26336.","DOI":"10.2196\/26336"},{"key":"877_CR22","doi-asserted-by":"crossref","unstructured":"Yuan N, Pevnick JM, Botting PG, et al. Patient use and clinical practice patterns of remote cardiology clinic visits in the era of COVID-19. JAMA Netw Open. 2021;4:e214157.","DOI":"10.1001\/jamanetworkopen.2021.4157"},{"key":"877_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ijgo.13340","volume":"151","author":"SM Strong","year":"2020","unstructured":"Strong SM, Magama Z, Mallick R, et al. Waiting for myomectomy during the COVID-19 pandemic: the vicious cycle of psychological and physical trauma associated with increased wait times. Int J Gynaecol Obstet. 2020;151:303\u20135.","journal-title":"Int J Gynaecol Obstet"},{"key":"877_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.5468\/ogs.21029","volume":"64","author":"S Saha","year":"2021","unstructured":"Saha S, Roy KK, Zangmo R, et al. Gynecological laparoscopic surgeries in the era of COVID-19 pandemic: a prospective study. Obstet Gynecol Sci. 2021;64:383\u20139.","journal-title":"Obstet Gynecol Sci"},{"key":"877_CR25","doi-asserted-by":"crossref","unstructured":"Carugno J, Di Spiezio Sardo A, Alonso L, et al. COVID-19 pandemic. Impact on hysteroscopic procedures: a consensus statement from the Global Congress of Hysteroscopy Scientific Committee. J Minim Invasive Gynecol. 2020;27:988\u201392.","DOI":"10.1016\/j.jmig.2020.04.023"},{"key":"877_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1097\/NMD.0000000000001403","volume":"209","author":"KM Brown","year":"2021","unstructured":"Brown KM, Robinson GE, Nadelson CC, et al. Psychological impact of COVID-19 on minority women. J Nerv Ment Dis. 2021;209:695\u20136.","journal-title":"J Nerv Ment Dis"},{"key":"877_CR27","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s10900-020-00944-3","volume":"46","author":"C Little","year":"2021","unstructured":"Little C, Alsen M, Barlow J, et al. The impact of socioeconomic status on the clinical outcomes of COVID-19; a retrospective cohort study. J Community Health. 2021;46:794\u2013802.","journal-title":"J Community Health"},{"key":"877_CR28","doi-asserted-by":"crossref","unstructured":"Batty GD, Gaye B, Gale CR, et al. Explaining ethnic differentials in COVID-19 mortality: cohort study. Am J Epidemiol. 2021.","DOI":"10.1093\/aje\/kwab237"},{"key":"877_CR29","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.3122\/jabfm.2021.S1.200338","volume":"34","author":"N Khanna","year":"2021","unstructured":"Khanna N, Klyushnenkova EN, Kaysin A. Association of COVID-19 with race and socioeconomic factors in family medicine. J Am Board Fam Med. 2021;34:S40\u20137.","journal-title":"J Am Board Fam Med"},{"key":"877_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1055\/s-0037-1607264","volume":"35","author":"A Al-Hendy","year":"2017","unstructured":"Al-Hendy A, Myers ER, Stewart E. Uterine fibroids: burden and unmet medical need. Semin Reprod Med. 2017;35:473\u201380.","journal-title":"Semin Reprod Med"},{"key":"877_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ijgo.13102","volume":"149","author":"E Giuliani","year":"2020","unstructured":"Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020;149:3\u20139.","journal-title":"Int J Gynaecol Obstet"},{"issue":"97","key":"877_CR32","first-page":"e1","volume":"213","author":"AL Nelson","year":"2015","unstructured":"Nelson AL, Ritchie JJ. Severe anemia from heavy menstrual bleeding requires heightened attention. Am J Obstet Gynecol. 2015;213(97):e1\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"877_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1701-2163(15)30338-8","volume":"37","author":"GA Vilos","year":"2015","unstructured":"Vilos GA, Allaire C, Laberge PY, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37:157\u201378.","journal-title":"J Obstet Gynaecol Can"},{"key":"877_CR34","unstructured":"Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47:1\u201329."},{"key":"877_CR35","doi-asserted-by":"crossref","unstructured":"Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women\u2013PREFER a randomized, placebo-controlled study. PLoS One. 2014;9:e94217.","DOI":"10.1371\/journal.pone.0094217"},{"key":"877_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/jn\/nxy265","volume":"149","author":"MJ Wenger","year":"2019","unstructured":"Wenger MJ, Rhoten SE, Murray-Kolb LE, et al. Changes in iron status are related to changes in brain activity and behavior in Rwandan female university students: results from a randomized controlled efficacy trial involving iron-biofortified beans. J Nutr. 2019;149:687\u201397.","journal-title":"J Nutr"},{"key":"877_CR37","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1089\/jwh.2012.3713","volume":"21","author":"AJ Friedman","year":"2012","unstructured":"Friedman AJ, Chen Z, Ford P, et al. Iron deficiency anemia in women across the life span. J Womens Health (Larchmt). 2012;21:1282\u20139.","journal-title":"J Womens Health (Larchmt)"},{"key":"877_CR38","doi-asserted-by":"crossref","unstructured":"Murji A, Lam M, Allen B, et al. Risks of preoperative anemia in women undergoing elective hysterectomy and myomectomy. Am J Obstet Gynecol. 2019;221:629e1-e18.","DOI":"10.1016\/j.ajog.2019.07.018"},{"key":"877_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/anae.13773","volume":"72","author":"M Mu\u00f1oz","year":"2017","unstructured":"Mu\u00f1oz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72:233\u201347.","journal-title":"Anaesthesia"},{"key":"877_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/TCRM.S147318","volume":"15","author":"M Farris","year":"2019","unstructured":"Farris M, Bastianelli C, Rosato E, et al. Uterine fibroids: an update on current and emerging medical treatment options. Ther Clin Risk Manag. 2019;15:157\u201378.","journal-title":"Ther Clin Risk Manag"},{"key":"877_CR41","first-page":"100","volume":"95","author":"MS De La Cruz","year":"2017","unstructured":"De La Cruz MS, Buchanan EM. Uterine fibroids: diagnosis and treatment. Am Fam Physician. 2017;95:100\u20137.","journal-title":"Am Fam Physician"},{"key":"877_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.rbmo.2020.05.017","volume":"41","author":"J Donnez","year":"2020","unstructured":"Donnez J, Dolmans MM. Hormone therapy for intramural myoma-related infertility from ulipristal acetate to GnRH antagonist: a review. Reprod Biomed Online. 2020;41:431\u201342.","journal-title":"Reprod Biomed Online"},{"key":"877_CR43","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/AOG.0b013e3182841594","volume":"121","author":"DL Clarke-Pearson","year":"2013","unstructured":"Clarke-Pearson DL, Geller EJ. Complications of hysterectomy. Obstet Gynecol. 2013;121:654\u201373.","journal-title":"Obstet Gynecol"},{"key":"877_CR44","doi-asserted-by":"publisher","first-page":"8247207","DOI":"10.1155\/2020\/8247207","volume":"2020","author":"E Beyan","year":"2020","unstructured":"Beyan E, Inan AH, Emirdar V, et al. Comparison of the effects of total laparoscopic hysterectomy and total abdominal hysterectomy on sexual function and quality of life. Biomed Res Int. 2020;2020:8247207.","journal-title":"Biomed Res Int"},{"key":"877_CR45","doi-asserted-by":"crossref","unstructured":"Laberge PY, Murji A, Vilos GA, et al. Guideline no. 389-medical management of symptomatic uterine leiomyomas \u2013 an addendum. J Obstet Gynaecol Can. 2019;41:1521\u20134.","DOI":"10.1016\/j.jogc.2019.01.010"},{"key":"877_CR46","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2147\/IJWH.S138982","volume":"9","author":"A Mas","year":"2017","unstructured":"Mas A, Tarazona M, Dasi Carrasco J, et al. Updated approaches for management of uterine fibroids. Int J Womens Health. 2017;9:607\u201317.","journal-title":"Int J Womens Health"},{"key":"877_CR47","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/GRF.0000000000000171","volume":"59","author":"CB Bartels","year":"2016","unstructured":"Bartels CB, Cayton KC, Chuong FS, et al. An evidence-based approach to the medical management of fibroids: a systematic review. Clin Obstet Gynecol. 2016;59:30\u201352.","journal-title":"Clin Obstet Gynecol"},{"key":"877_CR48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.steroids.2014.05.002","volume":"86","author":"W Jiang","year":"2014","unstructured":"Jiang W, Shen Q, Chen M, et al. Levonorgestrel-releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: a systematic review. Steroids. 2014;86:69\u201378.","journal-title":"Steroids"},{"key":"877_CR49","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1056\/NEJMoa1904351","volume":"382","author":"WD Schlaff","year":"2020","unstructured":"Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020;382:328\u201340.","journal-title":"N Engl J Med"},{"key":"877_CR50","doi-asserted-by":"crossref","unstructured":"Ali M, A RS, Al Hendy A. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Rev Clin Pharmacol. 2021;14:427\u201337.","DOI":"10.1080\/17512433.2021.1900726"},{"key":"877_CR51","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa2008283","volume":"384","author":"A Al-Hendy","year":"2021","unstructured":"Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384:630\u201342.","journal-title":"N Engl J Med"},{"key":"877_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.fertnstert.2020.02.114","volume":"114","author":"J Donnez","year":"2020","unstructured":"Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020;114:44\u201355.","journal-title":"Fertil Steril"},{"key":"877_CR53","doi-asserted-by":"crossref","unstructured":"Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017;11:CD000547.","DOI":"10.1002\/14651858.CD000547.pub2"},{"key":"877_CR54","doi-asserted-by":"crossref","unstructured":"Murji A, Whitaker L, Chow TL, et al. Selective progesterone receptor modulators (SPRMs) for uterine fibroids. Cochrane Database Syst Rev. 2017;4:CD010770.","DOI":"10.1002\/14651858.CD010770.pub2"},{"key":"877_CR55","doi-asserted-by":"crossref","unstructured":"Middelkoop MA, Bet PM, Drenth JPH, et al. Risk-efficacy balance of ulipristal acetate compared to surgical alternatives. Br J Clin Pharmacol. 2020.","DOI":"10.1111\/bcp.14708"},{"key":"877_CR56","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00404-020-05918-3","volume":"303","author":"N Shah","year":"2021","unstructured":"Shah N, Egbase E, Sideris M, et al. What happens after randomised controlled trials? Uterine fibroids and ulipristal acetate: systematic review and meta-analysis of \u201creal-world\u201d data. Arch Gynecol Obstet. 2021;303:1121\u201330.","journal-title":"Arch Gynecol Obstet"},{"key":"877_CR57","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12325-020-01555-z","volume":"38","author":"E Ekanem","year":"2021","unstructured":"Ekanem E, Talaulikar V. Medical therapy for fibroids: what next for ulipristal acetate? Adv Ther. 2021;38:137\u201348.","journal-title":"Adv Ther"},{"key":"877_CR58","doi-asserted-by":"crossref","unstructured":"Ciebiera M, Ali M, Prince L, et al. The evolving role of natural compounds in the medical treatment of uterine fibroids. J Clin Med. 2020;9.","DOI":"10.3390\/jcm9051479"},{"key":"877_CR59","unstructured":"Porcaro G, Angelozzi P. Uterine fibroid treatment with vitamin D combined with epigallocatechin gallate and vitamin B6: a controlled pilot study. IJMDAT. 2021;4:e300."},{"key":"877_CR60","doi-asserted-by":"crossref","unstructured":"Cope AG, Young RJ, Stewart EA. Non-extirpative treatments for uterine myomas: measuring success. J Minim Invasive Gynecol. 2021;28:442\u201352 e4.","DOI":"10.1016\/j.jmig.2020.08.016"},{"key":"877_CR61","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1016\/j.ultrasmedbio.2019.08.022","volume":"45","author":"JS Lee","year":"2019","unstructured":"Lee JS, Hong GY, Lee KH, et al. Safety and efficacy of ultrasound-guided high-intensity focused ultrasound treatment for uterine fibroids and adenomyosis. Ultrasound Med Biol. 2019;45:3214\u201321.","journal-title":"Ultrasound Med Biol"},{"key":"877_CR62","first-page":"77","volume":"14","author":"L Christoffel","year":"2021","unstructured":"Christoffel L, Romer T, Schiermeier S. Transcervical radiofrequency ablation of uterine fibroids global registry (SAGE): study protocol and preliminary results. Med Devices (Auckl). 2021;14:77\u201384.","journal-title":"Med Devices (Auckl)"}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-022-00877-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-022-00877-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-022-00877-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T15:39:25Z","timestamp":1650296365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-022-00877-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1007\/s43032-022-00877-3","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"N.L. has received funding\/grant support from AbbVie and Bayer, and honorarium for consultancy from AbbVie, Baxter, Bayer, and TerSera. M.L. has received funding\/grant support from AbbVie and the Australian Woman and Children\u2019s Foundation, and honorarium for consultancy from Bayer, GE Healthcare, and TerSera. A.M. has received funding\/grant support from AbbVie, and honorarium for consultancy from AbbVie, Bayer, and Pfizer. S.S. has received funding\/grant support from AbbVie, Allergan, and Bayer, and honorarium for consultancy from AbbVie, Allergan, Bayer, Myovant, and TerSera. A.A-H. has received funding\/grant support from the National Institute of Health and Crila, and honorarium for consultancy from AbbVie, Allergan, Bayer, Myovant, Novartis, and OBS-EVA. L.B. has received royalties from Elsevier, UpToDate, and Wolter Kluwers.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}